Lamzede (Velmanase Alfa-Tycv) Patent Expiration, LOE Window & CMS Spending

Lamzede (Velmanase Alfa-Tycv) by Chiesi Farmaceutici Spa: Biologic BLA (Purple Book Regime), 0 AB generics, $10.1M 2024 CMS Part D & Medicaid spend, and $4,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorChiesi Farmaceutici Spa
FDA Application & PathwayB761278 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$10.1M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$10.1M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($4,000 intro WAC)